Cigna®

Fax completed form to: (855) 840-1678
If this is an URGENT request, please call (800) 882-4462
(800.88.CIGNA)

Berinert, Cinryze, Firazyr, Haegarda, Kalbitor, Ruconest, Takhzyro

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		

Urgency:
☐ Standard ☐ Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)

Medication requested:
☐ Berinert 500 unit kit
☐ Cinryze 500 unit vial
☐ Firazyr 30mg/3ml syringe
☐ Haegarda 2000 unit vial ☐ Haegarda 3000 unit vial
☐ Icatibant 30mg/30ml syringe
☐ Kalbitor 30mg/3ml vial
☐ Ruconest 2100 unit vial
☐ Takhzyro 300/2ml vial

Directions for use: Quantity: Duration of therapy: J-Code:

(for Berinert, Haegarda or Ruconest) What is your patient's current weight (kg)? ICD10:

Is this a new start or continuation of therapy? If your patient has already begun treatment with drug samples, please choose "new start of therapy". ☐ new start of therapy ☐ continued established therapy- start date:

(if continued therapy) Has your patient had a good response to therapy with this drug (for example, decrease in frequency of HAE acute attacks, decrease in HAE attack severity, decrease in duration of HAE attacks)? ☐ Yes ☐ No
Please provide clinical support.

(if continued therapy and requesting Takhzyro at 300mg every 2 weeks dosing) Has there been an attempt to taper the dosing to 300mg every 4 weeks? ☐ Yes ☐ No
(if no) Please explain:

Where will this medication be obtained?

☐ Accredo Specialty Pharmacy**
☐ Hospital Outpatient
☐ Retail pharmacy
☐ Other (please specify):

☐ Home Health / Home Infusion vendor
☐ Physician's office stock (billing on a medical claim form)
***Cigna's nationally preferred specialty pharmacy*

*****Medication orders can be placed with Accredo via E-prescribe - Accredo (1640 Century Center Pkwy, Memphis, TN 38134-8822 | NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557*

Facility and/or doctor dispensing and administering medication:
Facility Name: State: Tax ID#:
Address (City, State, Zip Code):

Where will this drug be administered?

☐ Patient's Home ☐ Physician's Office
☐ Hospital Outpatient ☐ Other (please specify):

NOTE: *Per some Cigna plans, infusion of medication MUST occur in the least intensive, medically appropriate setting.*
Is this patient a candidate for re-direction to an alternate setting (such as alternate infusion site, physician's office, home) with assistance of a Specialty Care Options Case Manager? ☐ Yes ☐ No (provide medical necessity rationale):

Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? ☐ Yes ☐ No

Diagnosis related to use:

☐ hereditary angioedema (HAE) ☐ other (please specify):

Clinical Information:

****This drug requires supportive documentation (chart notes, lab and test results, etc). Supportive documentation for all answers must be attached with this request****

For all products:

****Supportive documentation for all answers must be attached with this request.****

Does your patient have a confirmed monoallelic mutation in either the SERPING1 or F12 gene which is known to cause HAE?
☐ Yes ☐ No ****documentation required**

(if no) Did your patient have a C4 level below the lower limit of normal as defined by the laboratory performing the test?
☐ Yes ☐ No ****documentation of labs required**

Did/does your patient have a C1 inhibitor (C1INH) antigenic level below the lower limit of normal as defined by the laboratory performing the test? ☐ Yes ☐ No ****documentation of labs required**

(if no) Did your patient have a C1INH functional level below the lower limit of normal as defined by the laboratory performing the test?
☐ Yes ☐ No ****documentation of labs required**

If your patient was/is taking any medications known to cause these attacks (for example: ACE-I, ARB, or estrogens), have these been evaluated and discontinued when appropriate?

☐ Yes, medications were evaluated and discontinued when appropriate
☐ Patient is/was not taking any known medications
☐ No
☐ Unknown

Is this drug being prescribed by, or in consultation with, an allergist/immunologist or a physician who specializes in the treatment of HAE or related disorders? ☐ Yes ☐ No

For Cinryze, Haegarda, Takhzyro:

****Supportive documentation for all answers must be attached with this request.****

Is this drug being used to prevent angioedema attacks? ☐ Yes ☐ No

Does your patient have a history of 2 or more moderate or severe attacks per month (for example airway swelling, severe abdominal pain, facial swelling, nausea and vomiting, painful facial distortion)? ☐ Yes ☐ No

While receiving the requested drug, will your patient also be treated with any of the following? (check all that apply)

☐ Cinryze ☐ Haegarda ☐ Takhzyro ☐ other (please specify):

For Firazyr and Icatibant:

****Supportive documentation for all answers must be attached with this request.****

Is this drug being used for the treatment of acute angioedema attacks with Hereditary Angioedema (HAE)?
☐ Yes ☐ No

Does your patient have a history of a moderate or severe attacks (for example: airway swelling, severe abdominal pain, facial swelling, nausea and vomiting, painful facial distortion)? ☐ Yes ☐ No

While receiving the requested drug, will your patient also be treated with any of the following? (check all that apply)

☐ Berinert
☐ Kalbitor
☐ Ruconest
☐ Sajazir
☐ other (please specify):

For Firazyr only- Has your patient tried a generic formulation of icatibant? ☐ Yes ☐ No

(if yes) Did your patient have a documented intolerance to icatibant? ☐ Yes ☐ No

For Ruconest:

****Supportive documentation for all answers must be attached with this request.****

Is this drug being used for treatment of acute angioedema attacks with Hereditary Angioedema (HAE)? ☐ Yes ☐ No

Does your patient have a history of moderate or severe attacks (for example abdominal, facial or peripheral [extremities])? ☐ Yes ☐ No

While receiving the requested drug, will your patient also be treated with any of the following? (check all that apply)
☐ Berinert ☐ Firazyr ☐ Icatibant ☐ Kalbitor ☐ Ruconest ☐ Sajazir
☐ other (please specify):

For Berinert and Kalbitor:

****Supportive documentation for all answers must be attached with this request.****

Is this drug being used for the treatment of acute angioedema attacks with Hereditary Angioedema (HAE)? ☐ Yes ☐ No

Does your patient have a history of a moderate or severe attacks for example, decrease in frequency of HAE acute attacks, decrease in HAE attack severity, decrease in duration of HAE attacks)? ☐ Yes ☐ No

While receiving the requested drug, will your patient also be treated with any of the following? (check all that apply)

☐ Berinert
☐ Kalbitor
☐ icatibant
☐ Firazyr
☐ Ruconest
☐ Sajazir
☐ other (please specify):

Additional pertinent information: *(include alternatives tried, date(s) taken and for how long, and what the documented results were of taking this drug, including any intolerances or adverse reactions your patient experienced):*

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature:_____ **Date:**_____

Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v111621

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005